MedTrace Logo

Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants

NCT02076373 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-11-23

No results posted yet for this study

Summary

The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the effect of intravenously administered recombinant human erythropoietin (Epo) as compared to placebo in preterm infants with brain damage on neurological development until five years od age.

Conditions

  • Intraventricular Hemorrhage of Prematurity

Interventions

DRUG

recombinant human Erythropoietin

i.v. administration

DRUG

Placebo

i.v. administration

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Sven Wellmann, MD · University of Zurich

  • Hans Ulrich Bucher, MD, PhD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
23 Weeks
Max Age
31 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • Austria
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076373 on ClinicalTrials.gov